Journal
MOLECULAR METABOLISM
Volume 42, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.molmet.2020.101092
Keywords
Dyslipidemia; NAFLD; Cardiovascular disease; Metabolic syndrome
Categories
Funding
- French National Research Agency [ANR-10-LABX-46, ANR-16-RHUS-0006]
- ERC Advanced Grant [694717]
- University of Lille
- Association Francaise pour l'Etude du Foie (AFEF)
- Fondation pour la Recherche Medicale
- Agence Nationale de la Recherche (ANR) [ANR-16-RHUS-0006] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a global health problem. Cardiovascular diseases (CVD) are the most common cause of mortality in NAFLD patients. NAFLD and CVD share several common risk factors including obesity, insulin resistance, and type 2 diabetes (T2D). Atherogenic dyslipidemia, characterized by plasma hypertriglyceridemia, increased small dense low-density lipoprotein (LDL) particles, and decreased high-density lipoprotein cholesterol (HDL-C) levels, is often observed in NAFLD patients. Scope of review: In this review, we highlight recent epidemiological studies evaluating the link between NAFLD and CVD risk. We further focus on recent mechanistic insights into the links between NAFLD and altered lipoprotein metabolism. We also discuss current therapeutic strategies for NAFLD and their potential impact on NAFLD-associated CVD risk. Major conclusions: Alterations in hepatic lipid and lipoprotein metabolism are major contributing factors to the increased CVD risk in NAFLD patients, and many promising NASH therapies in development also improve dyslipidemia in clinical trials. (c) 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available